Every indexed document

LLC equity research reports (including the disclosures in any such equity report or on

LLC assigns price targets on all companies covered in equity research unless noted otherwise. The equity research price target

LLC in order to prevent and avoid conflicts of

securities and other financial instruments may be difficult to value or sell and reliable

objectives or needs and are not intended as recommendations of investment strategy. The recipients of this report must make their own

but various regulations may prevent us from doing so. Research reports and commentaries are published at irregular intervals as appropriate in the analyst’s

https://cowenlibrary.bluematrix.com/client/library.jsp.

e-mailed or made available to third-party aggregators. Cowen and Company

Inc. and its affiliates is the proprietary and confidential property of NPD and was made available for publication herein by

sales and trading or principal trading revenues. Cowen and Company

LLC and or its affiliates make a market in the stock of GW Pharmaceuticals Plc

and (ii) no part of his or her compensation was

economic or market conditions. Commentaries produced by Cowen Washington Research Group are not

much work and change still needs to occur in order for this industry to

we believe this will be an attractive option for

18 of whom completed the 12 week treatment. At 12 weeks

and the company is testing numerous other cannabinoids. GW’s CBDV

while the p-values suggest that CBD has activity

headache (7% CBD vs. 8.9% placebo) and somnolence

many of which were other scales measuring functionality and